Back to News
Market Impact: 0.55
Revolution Medicines Reports Third Quarter 2026 Financial Results and RASONQUE Launch
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCorporate Earnings
Revolution Medicines said the FDA approved RASONQUE (daraxonrasib) on August 26, 2026, and the company has launched it commercially. The excerpt identifies the reported quarter as ending September 30, 2026, but provides no financial figures or complete details of the approved patient population.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment
RVMD0.90
More News
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook
- e.l.f. CEO: All of Our Brands Are Growing
- Behind Wall Street’s plunge: AI liquidation threatens Anthropic’s mega-IPO